KRAS Mutational Status as a Predictor of Epidermal Growth Factor Receptor Inhibitor Efficacy in Colorectal Cancer

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Mutational Status ◽

Epidermal Growth ◽

Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients

Oncology ◽

10.1159/000334919 ◽

2011 ◽

Vol 81 (5-6) ◽

pp. 359-364 ◽

Cited By ~ 9

Author(s):

Robert Königsberg ◽

Wolfgang Hulla ◽

Martin Klimpfinger ◽

Angelika Reiner-Concin ◽

Tanja Steininger ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Economic Aspects ◽

Mutational Status ◽

Epidermal Growth ◽

Colorectal Cancer Patients ◽

Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer

Clinical Pharmacokinetics ◽

10.1007/s40262-017-0590-9 ◽

2017 ◽

Vol 57 (4) ◽

pp. 455-473 ◽

Cited By ~ 4

Author(s):

Sander Ketzer ◽

Kirsten Schimmel ◽

Miriam Koopman ◽

Henk-Jan Guchelaar

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Pharmacokinetics And Pharmacodynamics ◽

Clinical Pharmacokinetics ◽

Epidermal Growth ◽

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-08-2961 ◽

2009 ◽

Vol 15 (9) ◽

pp. 3184-3188 ◽

Cited By ~ 217

Author(s):

Hans Prenen ◽

Jef De Schutter ◽

Bart Jacobs ◽

Wendy De Roock ◽

Bart Biesmans ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Major Determinant ◽

Pik3ca Mutations ◽

Epidermal Growth ◽

Economic impact in the management of dermatologic toxicities (dTs) induced by the epidermal growth factor receptor inhibitor (EGFRI) cetuximab in colorectal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3569 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3569-3569 ◽

Cited By ~ 1

Author(s):

J. H. Borovicka ◽

M. F. Mulcahy ◽

C. Calahan ◽

D. P. West ◽

M. E. Lacouture

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Economic Impact ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

KRAS Testing and Epidermal Growth Factor Receptor Inhibitor Treatment for Colorectal Cancer in Community Settings

Cancer Epidemiology Biomarkers & Prevention ◽

10.1158/1055-9965.epi-12-0545 ◽

2012 ◽

Vol 22 (1) ◽

pp. 91-101 ◽

Cited By ~ 20

Author(s):

Jennifer Webster ◽

Tia L. Kauffman ◽

Heather Spencer Feigelson ◽

Pamala A. Pawloski ◽

Adedayo A. Onitilo ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Community Settings ◽

Epidermal Growth ◽

Inhibitor Treatment ◽

Effective therapy of epidermal growth factor receptor inhibitor-associated dermatologic side effects in a patient with metastatic colorectal cancer: a and review of literature

Advances in Dermatology and Allergology ◽

10.5114/pdia.2012.30475 ◽

2012 ◽

Vol 4 ◽

pp. 324-329

Author(s):

Alicja Góralczyk ◽

Małgorzata Sokołowska-Wojdyło ◽

Anna Kowalczyk ◽

Aneta Szczerkowska-Dobosz ◽

Wioletta Barańska-Rybak

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Side Effects ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Review Of Literature ◽

Epidermal Growth ◽

Trichomegaly of the eyelashes induced by the epidermal growth factor receptor inhibitor cetuximab in the treatment of metastatic colorectal cancer

BMJ Case Reports ◽

10.1136/bcr-2018-228968 ◽

2019 ◽

Vol 12 (4) ◽

pp. e228968 ◽

Cited By ~ 2

Author(s):

Leonor Vasconcelos Matos ◽

Ana Pissarra ◽

Mariana Malheiro ◽

Ana Neto Plácido

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Trichomegaly of the Eyelashes After Colorectal Cancer Treatment With the Epidermal Growth Factor Receptor Inhibitor Cetuximab

Clinical Colorectal Cancer ◽

10.3816/ccc.2009.n.040 ◽

2009 ◽

Vol 8 (4) ◽

pp. 235 ◽

Cited By ~ 6

Author(s):

Richard Bambury ◽

J.A. McCaffrey

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Cancer Treatment ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Colorectal Cancer Treatment ◽

Faculty Opinions recommendation of PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1160729.622134 ◽

2009 ◽

Author(s):

Nicola Normanno ◽

Antonella De Luca

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Major Determinant ◽

Pik3ca Mutations ◽

Epidermal Growth ◽

Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines

Cancer Science ◽

10.1111/j.1349-7006.2009.01375.x ◽

2010 ◽

Vol 101 (2) ◽

pp. 440-447 ◽

Cited By ~ 21

Author(s):

Irene V. Bijnsdorp ◽

Frank A. E. Kruyt ◽

Masakazu Fukushima ◽

Kees Smid ◽

Shanti Gokoel ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Human Colorectal Cancer ◽

Human Colorectal Cancer Cell ◽

Colorectal Cancer Cell Lines ◽

Epidermal Growth ◽